BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Etanercept

Infection Risk; Tuberculosis

Risk of Infections

  • Infections, including serious infections leading to hospitalization or death, have been observed in patients treated with etanercept (see WARNINGS and ADVERSE REACTIONS).
  • Infections have included bacterial sepsis and tuberculosis.
  • Patients should be educated about the symptoms of infection and closely monitored for signs and symptoms of infection during and after treatment with etanercept
  • Patients who develop an infection should be evaluated for appropriate antimicrobial treatment and, in patients who develop a serious infection, etanercept should be discontinued.
  • Note: On 9/7/11, the FDA announced new revision to black box warning regarding the addition of the risk of infection from two bacterial pathogens, Legionella and Listeria.  (See FDA Announcement below)

Tuberculosis Infections

  • Tuberculosis (frequently disseminated or extrapulmonary at clinical presentation) has been observed in patients receiving TNF-blocking agents, including etanercept.
  • Tuberculosis may be due to reactivation of latent tuberculosis infection or to new infection.
  • Data from clinical trials and preclinical studies suggest that the risk of reactivation of latent tuberculosis infection is lower with etanercept than with TNF- blocking monoclonal antibodies. Nonetheless, postmarketing cases of tuberculosis reactivation have been reported for TNF blockers, including etanercept.
  • Patients should be evaluated for tuberculosis risk factors and be tested for latent tuberculosis infection prior to initiating etanercept and during treatment.
  • Treatment of latent tuberculosis infection should be initiated prior to therapy with etanercept.
  • Treatment of latent tuberculosis in patients with a reactive tuberculin test reduces the risk of tuberculosis reactivation in patients receiving TNF blockers.
  • Some patients who tested negative for latent tuberculosis prior to receiving etanercept have developed active tuberculosis.
  • Physicians should monitor patients receiving etanercept for signs and symptoms of active tuberculosis, including patients who tested negative for latent tuberculosis infection.

Malignancy in Children and Adolescents

  • Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including etanercept.

 


FDA and Industry Communications

Patient Counseling Information

Medication Guides

Patient Medication Guide

Package Inserts

Etanercept

Additional Information

Updated January 2018